COVID-19 continues to dominate biopharma nonprofit collaborations and grants in 2020, with the pandemic accounting for 85% of projected values reported this year, most of which have posted since the start of July.
Without a doubt, efforts to fight COVID-19 have dominated the flow of money into the biopharma industry through nonprofit collaborations and grants, accounting for 87% and 85% of the 2020 totals, respectively. Out of the 590 bio/nonprofit deals tracked by BioWorld this year, a total of $7.18 billion has been recorded, but 283 deals valued at $6.24 billion are directly focused on providing therapies for the pandemic.
Few would dispute that the best way to find innovative solutions to the COVID-19 pandemic is through industry, academia and government working together. BioWorld data indicate that more than 45% of the biopharma deals with nonprofit entities (bio/nonprofit) in 2020 are indeed focused on fighting the globally-disruptive SARS-CoV-2 virus.